Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents.
M LinJennifer R KramerD WhiteY CaoS Tavakoli-TabasiS MaduD SmithS M AschH B El-SeragF KanwalPublished in: Alimentary pharmacology & therapeutics (2017)
Half of patients with established HCV care were followed-up in the DAA era and only 29% received DAAs. Targeted efforts focusing on patient and system-levels may improve the reach of treatment with the new DAAs.